Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Receivables: 2009-2025

Historic Receivables for Prestige Consumer Healthcare (PBH) over the last 16 years, with Mar 2025 value amounting to $194.3 million.

  • Prestige Consumer Healthcare's Receivables rose 21.68% to $199.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $729.0 million, marking a year-over-year increase of 3.74%. This contributed to the annual value of $194.3 million for FY2025, which is 0.59% up from last year.
  • As of FY2025, Prestige Consumer Healthcare's Receivables stood at $194.3 million, which was up 0.59% from $193.2 million recorded in FY2024.
  • In the past 5 years, Prestige Consumer Healthcare's Receivables ranged from a high of $194.3 million in FY2025 and a low of $114.7 million during FY2021.
  • For the 3-year period, Prestige Consumer Healthcare's Receivables averaged around $191.6 million, with its median value being $193.2 million (2024).
  • Per our database at Business Quant, Prestige Consumer Healthcare's Receivables tumbled by 32.83% in 2021 and then soared by 38.70% in 2022.
  • Yearly analysis of 5 years shows Prestige Consumer Healthcare's Receivables stood at $114.7 million in 2021, then skyrocketed by 38.70% to $159.1 million in 2022, then grew by 17.71% to $187.2 million in 2023, then climbed by 3.17% to $193.2 million in 2024, then rose by 0.59% to $194.3 million in 2025.